新辅助治疗在胰腺癌中的作用：综述
The role of neoadjuvant therapy in pancreatic cancer: a review.
作者信息
Russo Suzanne, Ammori John, Eads Jennifer, Dorth Jennifer
机构信息
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
Department of Surgery, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA.
出版信息
Future Oncol. 2016 Mar;12(5):669-85. doi: 10.2217/fon.15.335. Epub 2016 Feb 1.
Abstract
Controversy remains regarding neoadjuvant approaches in the treatment of pancreatic cancer. Neoadjuvant therapy has several potential advantages over adjuvant therapy including earlier delivery of systemic treatment, in vivo assessment of response, increased resectability rate in borderline resectable patients and increased margin-negative resection rate. At present, there are no randomized data favoring neoadjuvant over adjuvant therapy and multiple neoadjuvant approaches are under investigation. Combination chemotherapy regimens including 5-fluorouracil, irinotecan and oxaliplatin, gemcitabine with or without abraxane, or docetaxel and capecitabine have been used in the neoadjuvant setting. Radiation and chemoradiation have also been incorporated into neoadjuvant strategies, and delivery of alternative fractionation regimens is being explored. This review provides an overview of neoadjuvant therapies for pancreatic cancer.
摘要
关于胰腺癌治疗中的新辅助治疗方法仍存在争议。新辅助治疗相对于辅助治疗有几个潜在优势，包括更早进行全身治疗、在体内评估反应、提高临界可切除患者的可切除率以及提高切缘阴性切除率。目前，尚无随机数据支持新辅助治疗优于辅助治疗，多种新辅助治疗方法正在研究中。新辅助治疗中使用的联合化疗方案包括5-氟尿嘧啶、伊立替康和奥沙利铂，吉西他滨联合或不联合白蛋白结合型紫杉醇，或多西他赛和卡培他滨。放疗和放化疗也已纳入新辅助治疗策略，并且正在探索替代分割方案的应用。本综述概述了胰腺癌的新辅助治疗。
相似文献
1
The role of neoadjuvant therapy in pancreatic cancer: a review.新辅助治疗在胰腺癌中的作用：综述
Future Oncol. 2016 Mar;12(5):669-85. doi: 10.2217/fon.15.335. Epub 2016 Feb 1.
2
Trends in Neoadjuvant Approaches in Pancreatic Cancer.新辅助治疗在胰腺癌中的应用趋势。
J Natl Compr Canc Netw. 2017 Aug;15(8):1070-1077. doi: 10.6004/jnccn.2017.0134.
3
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.可切除和交界可切除胰腺癌新辅助治疗和手术后首次疾病复发的放射学模式。
Surgery. 2020 Sep;168(3):440-447. doi: 10.1016/j.surg.2020.04.031. Epub 2020 Jul 5.
4
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.卡培他滨术前治疗联合放化疗治疗局部进展期胰腺癌
Ann Surg Oncol. 2011 Mar;18(3):619-27. doi: 10.1245/s10434-010-1456-7. Epub 2011 Jan 7.
5
Current status of adjuvant therapy for pancreatic cancer.胰腺癌辅助治疗的现状。
Oncologist. 2010;15(11):1205-13. doi: 10.1634/theoncologist.2010-0121. Epub 2010 Nov 2.
6
Neoadjuvant therapy for pancreas cancer: Global perspective and optimal care pathways in low to middle-income countries.胰腺癌的新辅助治疗：中低收入国家的全球视角和最佳护理路径。
J Surg Oncol. 2021 May;123(6):1441-1448. doi: 10.1002/jso.26365.
7
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.可切除交界性胰腺癌患者接受新辅助治疗和手术的生存情况。
Surgery. 2019 Sep;166(3):277-285. doi: 10.1016/j.surg.2019.05.010. Epub 2019 Jul 2.
8
Chemotherapy for pancreatic cancer.胰腺癌的化疗
Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. doi: 10.1016/j.lpm.2019.02.025. Epub 2019 Mar 15.
9
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.可切除胰腺腺癌的辅助和新辅助治疗
Chin Clin Oncol. 2017 Jun;6(3):26. doi: 10.21037/cco.2017.06.23.
10
Current standards and new innovative approaches for treatment of pancreatic cancer.胰腺癌治疗的现行标准与新创新方法。
Eur J Cancer. 2016 Apr;57:10-22. doi: 10.1016/j.ejca.2015.12.026. Epub 2016 Feb 4.
引用本文的文献
1
Neoadjuvant Stereotactic Ablative Radiotherapy in Pancreatic Ductal Adenocarcinoma: A Review of Perioperative and Long-Term Outcomes.胰腺导管腺癌的新辅助立体定向消融放疗：围手术期及长期结局综述
Diseases. 2025 Jul 8;13(7):214. doi: 10.3390/diseases13070214.
2
Combined PIVKA II and Vimentin-Guided EMT Tracking in Pancreatic Adenocarcinoma Combined Biomarker-Guided EMT Tracking in PDAC.联合PIVKA II和波形蛋白引导的胰腺癌上皮-间质转化追踪 胰腺癌联合生物标志物引导的上皮-间质转化追踪
Cancers (Basel). 2024 Jun 27;16(13):2362. doi: 10.3390/cancers16132362.
3
Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement.全新辅助治疗可提高伴有动脉受累的可切除边缘性胰腺癌患者的生存率。
Ann Gastroenterol Surg. 2023 Aug 10;8(1):151-162. doi: 10.1002/ags3.12726. eCollection 2024 Jan.
4
Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss.胰腺癌行胰十二指肠切除术之前进行放射治疗与手术时间延长及失血量增加有关。
World J Gastrointest Surg. 2023 Aug 27;15(8):1663-1672. doi: 10.4240/wjgs.v15.i8.1663.
5
Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.可切除和交界可切除胰腺导管腺癌的新辅助和辅助治疗：日本胰腺导管腺癌治疗的现状。
Gut Liver. 2023 Sep 15;17(5):698-710. doi: 10.5009/gnl220311. Epub 2023 Feb 27.
6
Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.新辅助放化疗与直接手术治疗可切除及交界可切除胰腺癌的比较：随机对照试验的Meta分析和试验序贯分析
Ann Hepatobiliary Pancreat Surg. 2023 Feb 28;27(1):28-39. doi: 10.14701/ahbps.22-052. Epub 2022 Dec 20.
7
Neoadjuvant therapy for pancreatic cancer.胰腺癌的新辅助治疗。
Updates Surg. 2022 Feb;74(1):35-42. doi: 10.1007/s13304-021-01186-1. Epub 2021 Oct 9.
8
PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.异常凝血酶原 II：一种用于诊断和监测胰腺腺癌患者的生物标志物。
PLoS One. 2021 May 20;16(5):e0251656. doi: 10.1371/journal.pone.0251656. eCollection 2021.
9
Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.新辅助 S-1 同步放化疗后 CT 影像评估对边界可切除胰腺癌手术 R0 切除率及胰周血管侵犯的相关性研究。
BMC Cancer. 2020 Dec 2;20(1):1184. doi: 10.1186/s12885-020-07698-0.
10
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.可切除及边界可切除胰腺腺癌新辅助放化疗联合或不联合全身化疗的疗效
Front Oncol. 2020 Sep 16;10:1461. doi: 10.3389/fonc.2020.01461. eCollection 2020.
本文引用的文献
1
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.新辅助改良FOLFIRINOX方案及放化疗用于局部晚期胰腺癌可提高手术切除率。
J Surg Oncol. 2015 Jun;111(8):1028-34. doi: 10.1002/jso.23921. Epub 2015 Jun 12.
2
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.基于FOLFIRINOX方案的新辅助治疗在可切除边缘或不可切除胰腺癌中的应用：已发表研究的荟萃分析综述
Pancreas. 2015 May;44(4):515-21. doi: 10.1097/MPA.0000000000000314.
3
Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor-vessel relationships.新辅助放化疗后对可切除边缘的胰腺癌进行切除并不取决于肿瘤与血管关系的影像学表现改善。
J Radiat Oncol. 2013 Dec;2(4):413-425. doi: 10.1007/s13566-013-0115-6. Epub 2013 Sep 22.
4
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.FOLFIRINOX新辅助治疗对局部晚期和边界可切除胰腺癌的放射学及外科意义
Ann Surg. 2015 Jan;261(1):12-7. doi: 10.1097/SLA.0000000000000867.
5
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.评估吉西他滨与立体定向体部放疗用于局部晚期不可切除胰腺腺癌患者的2期多机构试验。
Cancer. 2015 Apr 1;121(7):1128-37. doi: 10.1002/cncr.29161. Epub 2014 Dec 23.
6
Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.局部进展期胰腺腺癌：新辅助化疗和放疗后 CT 评估的反应。
Radiology. 2014 Oct;273(1):108-16. doi: 10.1148/radiol.14132914. Epub 2014 Jun 24.
7
Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).序贯新辅助放化疗（CRT）后行根治性手术与单纯一期手术治疗可切除、无转移的胰腺腺癌：NEOPA-一项随机多中心III期研究（NCT01900327、DRKS00003893、ISRCTN82191749）
BMC Cancer. 2014 Jun 7;14:411. doi: 10.1186/1471-2407-14-411.
8
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.一项新辅助吉西他滨和奥沙利铂治疗可切除胰腺腺癌患者的单臂、非随机 II 期临床试验。
Ann Surg. 2014 Jul;260(1):142-8. doi: 10.1097/SLA.0000000000000251.
9
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.术前短程放化疗联合质子治疗和卡培他滨及早期手术治疗可切除胰导管腺癌的 1/2 期和生物标志物研究。
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):830-8. doi: 10.1016/j.ijrobp.2014.03.034. Epub 2014 May 24.
10
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.基线代谢肿瘤体积和总病变糖酵解与接受立体定向体部放射治疗的局部晚期胰腺癌患者的生存结局相关。
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):539-46. doi: 10.1016/j.ijrobp.2014.02.031. Epub 2014 Apr 18.
Zotero 插件